Cargando…

STING activation in cancer immunotherapy

Cancer immunotherapy modulates and leverages the host immune system to treat cancer. The past decade has witnessed historical advancement of cancer immunotherapy. A myriad of approaches have been explored to elicit or augment anticancer innate immunity and/or adaptive immunity. Recently, activation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Ting, Zhang, Yu, Valerie, Kristoffer, Wang, Xiang-Yang, Lin, Shuibin, Zhu, Guizhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831454/ https://www.ncbi.nlm.nih.gov/pubmed/31695799 http://dx.doi.org/10.7150/thno.37574

Ejemplares similares

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
por: Su, Ting, et al.
Publicado: (2022)

Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy
por: Su, Ting, et al.
Publicado: (2023)

Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect
por: Cheng, Furong, et al.
Publicado: (2023)

A STING-Activating Nanovaccine for Cancer Immunotherapy
por: Luo, Min, et al.
Publicado: (2017)

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy
por: Luo, Kewang, et al.
Publicado: (2022)

cGAS-STING, an important pathway in cancer immunotherapy
por: Jiang, Minlin, et al.
Publicado: (2020)

Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
por: Li, Anping, et al.
Publicado: (2019)

Development of Small-Molecule STING Activators for Cancer Immunotherapy
por: Jung, Hee Ra, et al.
Publicado: (2021)

Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
por: Zheng, Juyan, et al.
Publicado: (2020)

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
por: Motedayen Aval, Leila, et al.
Publicado: (2020)

cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy
por: Long, Zi-Jie, et al.
Publicado: (2022)

Stinging insect allergy: current perspectives on venom immunotherapy
por: Ludman, Sian W, et al.
Publicado: (2015)

STING: a master regulator in the cancer-immunity cycle
por: Zhu, Yuanyuan, et al.
Publicado: (2019)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer
por: Dan, Qinfu, et al.
Publicado: (2023)

T‐cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy
por: Hansen, Aida S., et al.
Publicado: (2023)

Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy
por: Go, Eun-Jin, et al.
Publicado: (2020)

Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways
por: Li, Kai, et al.
Publicado: (2017)

Engineering cGAS-agonistic oligonucleotides as therapeutics and vaccine adjuvants for cancer immunotherapy
por: Zhou, Shurong, et al.
Publicado: (2023)

STING Signaling and Skin Cancers
por: Sato, Sayaka, et al.
Publicado: (2021)

Cancer Immunotherapy based on Image-guided STING Activation by Nucleotide Nanocomplex-Decorated Ultrasound Microbubbles
por: Li, Xuefeng, et al.
Publicado: (2022)

Cancer immunotherapy strategies that target the cGAS-STING pathway
por: Tian, Zhuoying, et al.
Publicado: (2022)

The Activation of cGAS-STING in Acute Kidney Injury
por: Sun, Chuanchuan, et al.
Publicado: (2023)

Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
por: Huang, Cuiqing, et al.
Publicado: (2023)

Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy
por: Shae, Daniel, et al.
Publicado: (2019)

Correction: Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
Publicado: (2022)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Tumor-targeted delivery of a STING agonist improves cancer immunotherapy
por: Wu, You-tong, et al.
Publicado: (2022)

Optogenetic engineering of STING signaling allows remote immunomodulation to enhance cancer immunotherapy
por: Dou, Yaling, et al.
Publicado: (2023)

The cGAS-STING Pathway: A Promising Immunotherapy Target
por: Ou, Liang, et al.
Publicado: (2021)

cGAS-STING pathway in cancer biotherapy
por: Wang, Yang, et al.
Publicado: (2020)

STING Agonists as Cancer Therapeutics
por: Amouzegar, Afsaneh, et al.
Publicado: (2021)

Responsive manganese-based nanoplatform amplifying cGAS-STING activation for immunotherapy
por: He, Qingbin, et al.
Publicado: (2023)

Combination of irinotecan silicasome nanoparticles with radiation therapy sensitizes immunotherapy by modulating the activation of the cGAS/STING pathway for colorectal cancer
por: Wang, Lu, et al.
Publicado: (2023)

Delivery of nucleic acid therapeutics for cancer immunotherapy
por: Zhou, Shurong, et al.
Publicado: (2020)

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
por: Ni, Qianqian, et al.
Publicado: (2020)

Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer
por: Sokač, Mateo, et al.
Publicado: (2022)

STING and liver disease
por: Chen, Can, et al.
Publicado: (2021)

Dampened STING-Dependent Interferon Activation in Bats
por: Xie, Jiazheng, et al.
Publicado: (2018)

Remodeling of Tumor Microenvironment by Nanozyme Combined cGAS–STING Signaling Pathway Agonist for Enhancing Cancer Immunotherapy
por: Dong, Wenpei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d879uvuba1fof8sbt18jlm0h2k